CureVac Stock Ceases Trading Following BioNTech Acquisition
21.01.2026 - 15:11:04 | boerse-global.de
The CureVac share has officially been delisted from public markets, marking the conclusion of its independent trading history. This final step comes after BioNTech successfully completed its full acquisition of the company. A critical deadline now approaches for former minority shareholders seeking to reclaim Dutch withholding tax.
BioNTech finalized the post-offer restructuring on January 6, 2026, merging CureVac N.V. into CureVac Merger B.V. This gave BioNTech complete ownership of all operational activities. Subsequently, the formal delisting from the Nasdaq exchange occurred on January 16, 2026, ending all public trading.
Key transaction details include:
* Total Consideration: Approximately $1.25 billion, paid in BioNTech shares
* Tender Acceptance: 86.75% of CureVac shares Read more...
So schätzen die Börsenprofis CureVac Aktien ein!
Für. Immer. Kostenlos.
